Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
Search Articles:
FDA grants orphan-drug designation to Astellas for development of FLT3 inhibitor for AML
Astellas Pharma announced the FDA granted orphan-drug designation to gilteritinib in patients with acute myeloid leukemia. Gilteritinib is a receptor tyrosine kinase inhibitor of FLT3 and AXL, which are involved in the growth of cancer cells.
July 20, 2017
More...
Email This Page
to a Friend
Print This
Page